<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[earnings per share and merck Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/earnings+per+share+and+merck.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to earnings per share and merck]]></description>
	<s:counts start="0" returned="20" found="24" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Pfizer Lifts Dividend, Yield Closer to Rivals]]></title>
		<link><![CDATA[http://www.bnet.com/2407-14055_23-374811.html]]></link>
		<description><![CDATA[NEW YORK (<a href="http://resources.bnet.com/index.php?source=ReutersUK">Reuters UK</a>) - Pfizer PFE, which halved its industry-topping dividend in January to finance its recent acquisition of Wyeth, boosted the dividend 12.5 percent on Monday.Shares of the world's largest drugmaker rose modestly after the dividend increase, which had been expected by many investors. The rise was within...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Thu, 17 Dec 2009 03:31:29 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/dividend.html"><![CDATA[Dividend]]></category>
		<category domain="http://resources.bnet.com/topic/financial+planning.html"><![CDATA[Financial Planning]]></category>
		<category domain="http://resources.bnet.com/topic/barclay.html"><![CDATA[Barclay]]></category>
		<category domain="http://resources.bnet.com/topic/bristol-myers+squibb+co..html"><![CDATA[Bristol-Myers Squibb Co.]]></category>
		<category domain="http://resources.bnet.com/topic/eli+lilly+%2526+co..html"><![CDATA[Eli Lilly & Co.]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BMY</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">LLY</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">BMY,LLY,MRK,PFE,WYE</category>
	</item>
	<item>
		<title><![CDATA[J&J to Slash 7,000 to 8,000 Jobs]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/news-analysis/slash-7000-8000-jobs/18696/]]></link>
		<description><![CDATA[NEW YORK (<a href="http://resources.bnet.com/index.php?source=Reuters">Reuters</a>) - Johnson & Johnson said on Tuesday it plans to cut 6 percent to 7 percent of its workforce in a battle to prop up profits in the face of generic competition to its prescription drugs. The company said the cuts will affect 7,000 to 8,000 jobs,...]]></description>
		<s:doctype><![CDATA[News items]]></s:doctype>
		<pubDate>Tue, 03 Nov 2009 07:52:25 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">JNJ</category>
	</item>
	<item>
		<title><![CDATA[Caterpillar Blows Out Earnings Through Lower Costs]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F150222-caterpillar-blows-out-earnings-through-lower-costs%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Ockham Research submits:  The stock market is pointed higher on Tuesday morning in large part because of five Dow components reporting earnings that have beaten expectations.  Coca-Cola KO, DuPont DD, Caterpillar CAT, United Technologies UTX, and Merck MRK all reported earnings today and each of these stocks are...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Tue, 21 Jul 2009 12:17:40 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/materials%252findustrials.html"><![CDATA[Materials/Industrials]]></category>
		<category domain="http://resources.bnet.com/topic/ockham+research.html"><![CDATA[Ockham Research]]></category>
		<category domain="http://resources.bnet.com/topic/caterpillar+inc..html"><![CDATA[Caterpillar Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CAT</category>
		<category domain="tickers">CAT</category>
	</item>
	<item>
		<title><![CDATA[Ranking of 20 Drug Companies' Sales Forces Shows Productivity Flat or Declining]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001144/ranking-of-20-drug-companies-sales-forces-shows-productivity-flat-or-declining/]]></link>
		<description><![CDATA[A ranking of drug company sales productivity shows Gilead gets the most revenues in return for every dollar invested in reps and marketing.    At the other end of the table, Sepracor gets the least bang for its sales, general and administrative buck see table below.  ...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 24 Feb 2009 09:47:51 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force.html"><![CDATA[Sales Force]]></category>
		<category domain="http://resources.bnet.com/topic/drug+company.html"><![CDATA[Drug Company]]></category>
		<category domain="http://resources.bnet.com/topic/genentech+inc..html"><![CDATA[Genentech Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sepracor+inc..html"><![CDATA[Sepracor Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DNA</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">SEPR</category>
		<category domain="tickers">DNA,PFE,SEPR</category>
	</item>
	<item>
		<title><![CDATA[Pfizer's Wyeth Buy Eclipses $2.3 Bill. Bextra Troubles; 19,000 Layoffs to Come]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000636/pfizers-wyeth-buy-eclipses-23-bill-bextra-troubles-19000-layoffs-to-come/]]></link>
		<description><![CDATA[Today's announcement that Pfizer is to acquire Wyeth for $68 million eclipsed some things that on any other day would have been headline news in themselves: a) The fact that Pfizer's earnings were down 90 percent due to a $2.3 billion settlement with the Department of Justice over its off-label...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 26 Jan 2009 08:54:10 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://resources.bnet.com/topic/layoff.html"><![CDATA[Layoff]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/mergers+%2526+acquisitions.html"><![CDATA[Mergers & Acquisitions]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+law.html"><![CDATA[Corporate Law]]></category>
		<category domain="http://resources.bnet.com/topic/litigation.html"><![CDATA[Litigation]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">PFE,WYE</category>
	</item>
	<item>
		<title><![CDATA[Pharmaceutical Product Development, Inc., 2009 Guidance Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14046_23-262445.html]]></link>
		<description><![CDATA[ Earnings Call ExcerptPharmaceutical Product Development, Inc. PPDI 2009 Guidance Call  January 15, 2009 9:00 am ET Executives  Dr. Fredric N. Eshelman - Vice Chairman and Chief Executive Officer Daniel G. Darazsdi - Chief Financial Officer William J. Sharbaugh - Chief Operating Officer Analysts John Kreger - William...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Thu, 15 Jan 2009 10:57:17 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[Revenue]]></category>
		<category domain="http://resources.bnet.com/topic/guidance.html"><![CDATA[Guidance]]></category>
		<category domain="http://resources.bnet.com/topic/dr..html"><![CDATA[Dr.]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/pharmaceutical+product+development+inc..html"><![CDATA[Pharmaceutical Product Development Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/gaap.html"><![CDATA[GAAP]]></category>
		<category domain="http://resources.bnet.com/topic/operational+accounting.html"><![CDATA[Operational Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/financial+accounting.html"><![CDATA[Financial Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PPDI</category>
		<category domain="tickers">PPDI</category>
	</item>
	<item>
		<title><![CDATA[Neurogen Corporation Q2 2008 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-223567.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator  Thank you. Operator instructions And our first question comes from the line of Kim Lee with Pacific Growth Equities. Please proceed. Kim Lee &#8211; Pacific Growth Equities  Good morning. Steve Davis  Good morning, Kim. Kim Lee &#8211; Pacific Growth Equities  Two questions. First,...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Tue, 02 Sep 2008 01:52:10 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/neurogen+corp..html"><![CDATA[Neurogen Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NRGN</category>
		<category domain="tickers">NRGN</category>
	</item>
	<item>
		<title><![CDATA[Dynavax Technologies Corporation Q4 2007 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-229941.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator  Thank you.  Operator Instructions.  We will take our first question from Bret Holley with Oppenheimer & Company. Bret Holley Yeah, hi.  Thanks for taking my questions.  I had a question about any additional market research you have done following the Merck...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Tue, 19 Feb 2008 15:48:10 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/dynavax+technologies+corp..html"><![CDATA[Dynavax Technologies Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DVAX</category>
		<category domain="tickers">DVAX</category>
	</item>
	<item>
		<title><![CDATA[ImClone Systems Inc. Q3 2007 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-232494.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator  [Operator Instructions].  Your first question comes from May-Kin Ho of Goldman Sachs.  May-Kin Ho - Goldman Sachs  Hi. I guess, I wanted to ask question about really how your payment from Bristol would be recognized and how we should going forward project out...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Thu, 25 Oct 2007 22:32:15 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/imclone+systems+inc..html"><![CDATA[ImClone Systems Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">IMCL</category>
		<category domain="tickers">IMCL</category>
	</item>
	<item>
		<title><![CDATA[Applera Corporation F1Q08 (Qtr End 9/30/07) Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14046_23-232503.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator  Thank you sir. [Operator&#8217;s instructions.]  One moment while we compile a list of questions. Our first question will come from the line of Ross Muken of Deutsche Bank, please proceed.  Ross Muken &#8211; Deutsche Bank  Good morning everyone.  Mark P. Stevenson &#8211;...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Thu, 25 Oct 2007 22:00:10 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/applera+corp..html"><![CDATA[Applera Corp.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">ABI</category>
		<category domain="tickers">ABI</category>
	</item>
	<item>
		<title><![CDATA[GlaxoSmithKline Q3 2007 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-232643.html]]></link>
		<description><![CDATA[ Question-and-Answer Session Operator Our first question comes from Tim Anderson. Please state your questions sir, announce the company name and location please. Tim Anderson - Stanford Bernstein Thank you, Tim Anderson at Stanford Bernstein in New York. Couple of questions. On Cervarix, can you update us on how you...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Wed, 24 Oct 2007 09:51:53 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/glaxosmithkline+plc..html"><![CDATA[GlaxoSmithKline Plc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GSK</category>
		<category domain="tickers">GSK</category>
	</item>
	<item>
		<title><![CDATA[Merck Reports Double-Digit Revenue and Earnings-Per-Share Growth for Third-Quarter 2007]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_Oct_22/ai_n21054919]]></link>
		<description><![CDATA[* Company Announces Third-Quarter 2007 Earnings Per Share EPS of $0.75, Excluding Restructuring Charges; Third-Quarter Reported EPS of $0.70]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 22 Oct 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[DaimlerChrysler Q2 2007 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14028_23-232966.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator Instructions Friedrich Lauer We take the first question from Johan Grabe, please. Johan Grabe - Deutsche Bank Yes, good afternoon. Johan Grabe, Deutsche Bank. Three questions if I may. First of all on Mercedes on your updated margin guidance I wonder whether you could provide the...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Wed, 25 Jul 2007 14:10:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://resources.bnet.com/topic/daimlerchrysler+ag.html"><![CDATA[DaimlerChrysler AG]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">DCX</category>
		<category domain="tickers">DCX</category>
	</item>
	<item>
		<title><![CDATA[Merck Anticipates Higher Than Expected First-Quarter Results; Raises Full-Year 2007 Earnings Per Share Guidance]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_April_12/ai_n27201172]]></link>
		<description><![CDATA[WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. announced today that, subject to final review of its first-quarter results, it anticipates its first-quarter earnings per share EPS will be $0.84, excluding restructuring charges related to site closures and position eliminations, and its reported EPS will be $0.78. Merck attributed these...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 12 Apr 2007 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/earnings+per+share.html"><![CDATA[earnings per share]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Merck Announces First Quarter Earnings Per Share Guidance and Raises Full-Year 2007 Earnings Per Share Guidance]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2007_Feb_28/ai_n27306515]]></link>
		<description><![CDATA[WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. announced today that it anticipates its first-quarter earnings per share EPS will be $0.63 to $0.67, excluding restructuring charges related to site closures and position eliminations, and anticipates reported first-quarter EPS of $0.58 to $0.64. Merck attributed these anticipated results to early...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 28 Feb 2007 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/earnings+per+share.html"><![CDATA[earnings per share]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Merck Continues to Anticipate Earnings Per Share  Growth in 2007; Reaffirms Long-Term, Double-Digit Compound Annual EPS Growth from 2005 to 2010, Excluding One-Time Items and Restructuring Charges]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_Dec_6/ai_n27076541]]></link>
		<description><![CDATA[* Full-Year 2006 Anticipated EPS Range of $2.48 to $2.52, Excluding Restructuring Charges; Reported 2006 EPS Range of $2.18 to $2.25]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 06 Dec 2006 00:00:00 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/earnings+per+share.html"><![CDATA[earnings per share]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/restructuring+charge.html"><![CDATA[Restructuring Charge]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Merck Announces Strong Financial Results for the Third Quarter 2006 Led by the Performance of SINGULAIR, VYTORIN and Vaccines]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_Oct_20/ai_n27034879]]></link>
		<description><![CDATA[* Company Posts Third-Quarter Earnings Per Share EPS of 51 Cents, Including the Impact of Reserving an Additional $598 Million Solely for Future VIOXX Legal Defense Costs and Excluding Restructuring Charges; Reported Third-Quarter EPS of 43 Cents]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 20 Oct 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/performance.html"><![CDATA[performance]]></category>
		<category domain="http://resources.bnet.com/topic/vaccine.html"><![CDATA[vaccine]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Merck Anticipates Higher Than Expected First-Quarter Results; Reaffirms Full-Year 2006 Earnings Per Share  Guidance]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2006_April_4/ai_n26816241]]></link>
		<description><![CDATA[WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. announced today that it anticipates its first-quarter EPS will be $0.71 to $0.75, excluding restructuring charges, and anticipates reported first-quarter EPS of $0.61 to $0.67. Merck attributed these anticipated results to strong ZOCOR revenue performance in the first quarter and the timing...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 04 Apr 2006 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
	<item>
		<title><![CDATA[Biomet F3Q06 (Qtr Ending Feb 28, 2006) Earnings Conference Call Transcript (BMET)]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14046_23-235655.html]]></link>
		<description><![CDATA[ Earnings Call Excerpt  Biomet, Inc. BMET  Q3 2006 Earnings Conference Call  March 21, 2006, 10:00 a.m. EST  Executives:  Dane A. Miller, Ph.D., President and Chief Executive Officer  Bart J. Doedens, M.D., Vice President, Biomet, Inc., President, EBI, L.P.  Gregory D. Hartman, Senior...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<pubDate>Tue, 21 Mar 2006 13:42:32 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/biomet+inc..html"><![CDATA[Biomet Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BMET</category>
		<category domain="tickers">BMET</category>
	</item>
	<item>
		<title><![CDATA[Merck Anticipates Higher Than Expected First Quarter Results; Reaffirms Full-Year 2005 Earnings Per Share Guidance]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2005_April_13/ai_n13606174]]></link>
		<description><![CDATA[WHITEHOUSE STATION, N.J. -- Merck & Co., Inc. announced today that it anticipates its first quarter earnings per share EPS will be 62 cents, subject to final review of its first quarter results. Merck attributed these anticipated results to a number of factors including ongoing cost management, the favorable impact...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 13 Apr 2005 00:00:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/earnings+per+share.html"><![CDATA[earnings per share]]></category>
		<category domain="http://resources.bnet.com/topic/merck+%2526+co.+inc..html"><![CDATA[Merck & Co. Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MRK</category>
		<category domain="tickers">MRK</category>
	</item>
</channel>
</rss>
